Immunity to varicella-zoster virus in patients before and after lung transplantatio

Completed

• Conditions: herpes zoster; shingles; 10027665; 10047438; 10013369

• Registration Number: NL-OMON43319
• Lead Sponsor: niversitair Medisch Centrum Groningen

Brief Summary

Trial is onging in other countries

Detailed Description

Not available

Study Timeline

• Study Completion: 2021-05-02
• Last Update Posted: 23 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 105

Inclusion Criteria

• Provision of written informed consent
• >=18 years of age;(for the part evaluating vaccination)
• Intended administration of VZV vaccine

Exclusion Criteria

• Pregnancy;(for the part evaluating vaccination)
• No administration of VZV vaccine due to any reason

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Cellular immunity is chosen as the primary objective as this measure is known<br /><br>to be more important than humoral immunity in the defence to VZV.<br /><br>Main study endpoint will be changes in cellular immunity pre-vaccination, 2<br /><br>weeks and 3 months after vaccination, and 3 months after lung transplantation.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>As secondary objectives humoral immunity and control parameters will be<br /><br>determined. Furthermore, herpes zoster incidence will be registered. </p><br>